Keeney M, Halley JG, Rhoads DD, et al. Marked variability in reported minimal residual disease lower level of detection of 4 hematolymphoid neoplasms: a survey of participants in the college of american pathologists' flow cytometry proficiency testing program. Arch Pathol Lab Med. 2015. [Epub ahead of print].
Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27:1659-1665. Abstract
Ladetto M, Bruggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299-1307. Abstract
Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126:964-971. Abstract
Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116-1123. Abstract
Bassan R, Spinelli O, Oldani E, et al. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014;4:e225.
Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20:1307-1313. Abstract
Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980-988. Abstract
Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125:1932-1935. Abstract
Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073-3079. Abstract
Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679-3687. Abstract
Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541-549. Abstract

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author

Aaron C. Logan, MD, PhD

Assistant Professor of Clinical Medicine, Hematology and Blood and Marrow Transplantation, University of California, San Francisco

Disclosures

Disclosure: Aaron C. Logan, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Pharmacyclics, Inc.

Dr Logan does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Logan does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Joanne M. Faysal, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joanne M. Faysal, MS, has disclosed no relevant financial relationships.

Sara Fagerlie, PhD, CHCP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sara Fagerlie, PhD, CHCP has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

The Role of MRD in Hematologic Malignancies

Authors: Aaron C. Logan, MD, PhD
CME Released: 9/25/2015
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/25/2016

Start Activity

Target Audience and Goal Statement

This activity is intended for hematologists, oncologists, and other clinicians caring for patients with hematologic malignancies.

The goal of this activity is to understand MRD and methods of detection, assess the utility of MRD in the clinical setting, and how it is used in the management of patients with ALL, CLL, NHL, and MM.

Upon completion of this activity, participants will be able to:

Define MRD and review methods of detection
Examine the utility of MRD testing for the assessment of disease status and its effect on treatment decisions
Differentiate the role of MRD in the management of patients with lymphoid malignancies

Disclosures

Author

Aaron C. Logan, MD, PhD

Assistant Professor of Clinical Medicine, Hematology and Blood and Marrow Transplantation, University of California, San Francisco

Disclosures

Disclosure: Aaron C. Logan, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Pharmacyclics, Inc.

Dr Logan does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Logan does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Joanne M. Faysal, MS

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joanne M. Faysal, MS, has disclosed no relevant financial relationships.

Sara Fagerlie, PhD, CHCP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sara Fagerlie, PhD, CHCP has disclosed no relevant financial relationships.

CME Reviewer

Robert Morris, PharmD

Associate CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME

The Role of MRD in Hematologic Malignancies

Authors: Aaron C. Logan, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 9/25/2015

Valid for credit through: 9/25/2016

processing....

This feature requires the newest version of Flash. You can download it here.

CME Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Author

Aaron C. Logan, MD, PhD

Editor(s)

Joanne M. Faysal, MS

Sara Fagerlie, PhD, CHCP

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

CME

The Role of MRD in Hematologic Malignancies

Target Audience and Goal Statement

Disclosures

Author

Aaron C. Logan, MD, PhD

Editor(s)

Joanne M. Faysal, MS

Sara Fagerlie, PhD, CHCP

CME Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Role of MRD in Hematologic Malignancies